Facebook
Twitter
LinkedIn
ForwardCardiovascular Disease Prevention
Course Topics
The ABCs of Primary and Secondary Prevention of Cardiovascular Disease
In recent years, improvements in outcomes related to cardiovascular disease have been due in part to the prioritization and progress of primary and secondary prevention efforts. Dr. Roger S. Blumenthal, an expert in the pathogenesis, treatment and prevention of cardiovascular disease, will compare and contrast the AHA/ACC and European guidelines and discuss the evidence for the changes in cardiovascular risk assessment guidelines.
Dr. Blumenthal was the principal developer of Johns Hopkins’ Ciccarone Center for the Prevention of Cardiovascular Disease and is an official national spokesperson for the American Heart Association. He has co-written more than 700 articles dealing with many aspects of coronary heart disease and cardiovascular disease management.
Aspirin and Cardiac Disease Prevention
Who should be taking aspirin as prevention for heart disease? The efficacy of aspirin as secondary prevention –– to prevent another event in people who have had a heart attack or other cardiac disease –– is firmly established. However, whether people with no known cardiovascular disease should take daily aspirin as primary prevention –– to reduce their risk of a first event –– remains a highly controversial topic in preventive medicine. Dr. Blaha will provide some insight into this question by discussing primary prevention and cardiac CT, cardiac disease prevention as primary prevention –– with specific cases to illustrate his point –– and whether patients with no existing atherosclerotic disease should use aspirin.
Target Audience
Internal medicine physicians, general practitioners, gastroenterologists, surgeons, physician assistants, residents, nurses, nurse practitioners, cardiologists, interventional cardiologists, cardiothoracic surgeons, vascular surgeons, interventional radiologists, echocardiographers, pulmonologists, hematologists, general internists, primary care physicians, intensivists, emergency medicine physicians, hospitalists, pharmacists, respiratory therapy and technologists and other interested healthcare providers.
Learning Objectives
- Explain the rationale for changes in 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.
- Apply the comprehensive “ABCDE” approach for all cardiovascular disease patients.
- Examine the evidence supporting aggressive medical and lifestyle management of cardiovascular disease and recognize cardiac prevention as primary prevention.
- Discuss the use of aspirin in patients with no previous atherosclerotic cardiovascular disease.
- Identify patients who should be taking aspirin as primary prevention.
Roger S. Blumenthal, M.D., FACC, FAHA, FNLA
Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Kenneth Jay Pollin Professor of Cardiology, Professor of Medicine, Johns Hopkins Hospital
Baltimore, Maryland
Michael J. Blaha, M.D., MPH
Director of Clinical Research
Ciccarone Center for the Prevention of Cardiovascular Disease
Professor of Medicine
Johns Hopkins Medicine
Baltimore, Maryland
Michael J. Blaha, M.D., MPH, faculty for this educational activity, is a researcher for Bayer, Novo Nordisk, and Amgen and a consultant for Kowa and Emocah. Dr. Blaha is also an adviser for Amgen, Novartis, Novo Nordisk, Bayer, Roche, 89BIO, Kaleido, and Inozyme and an independent contractor for Bayer, Novo Nordisk, and Amgen.
Roger S. Blumenthal, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Theodore Feldman, M.D., FACC, FACP
Medical Director, Prevention and Community Health
Co-Medical Director, Lipid and Cardiometabolic Management Program
Miami Cardiac & Vascular Institute
Baptist Health South Florida
Head of Cardiology, Clinical Associate Professor of Medicine
Florida International University Herbert Wertheim College of Medicine
Michael B. Phillips, M.D., FACP
Assistant Professor of Medicine
Consultant, Division of Community
Internal Medicine
Mayo Clinic Florida
John F. Rubin, M.D., FACP
Internal Medicine Physician
Co-Chair BRRH CME Committee
Boca Raton Regional Hospital
Baptist Health South Florida
Kenneth R. Rosenthal, M.D., FACP, FACG,AGAF
Gastroenterologist
Co-Chair BRRH CME Committee
Boca Raton Regional Hospital
Baptist Health South Florida
Theodore Feldman, M.D., FACC, FACP, conference director of this educational activity, is a member of the speakers’ bureau for Novo Nordisk, AstraZeneca, Eli Lilly and Boeringer Ingelheim. Dr. Feldman has an executive role with Rightway Healthcare and is an owner of Cadence Solutions.
Michael B. Phillips, M.D., FACP, conference director for this educational activity, has no relevant financial relationship with ineligible companies* to disclose.
Kenneth R. Rosenthal, M.D., conference director for this educational activity, is a member of the speakers’ bureau with Abbvie.
John F. Rubin, M.D., conference director for this educational activity, has stock options with Astra Zeneca and Bristol Myers Squibb.
All of the relevant financial relationships listed for these individuals have been mitigated.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Your participation information will be shared with specialty boards through the ACCME's PARS reporting system. Successful completion of a course examination is required. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Available Credit
- 1.50 ABIM MOC II
- 1.50 AMA PRA Category 1 Credit™
- 1.50 General certificate of attendance
- 1.50 Nurse Practitioners
- 1.50 Florida Board of Nursing
- 1.50 Florida Board of Pharmacy
- 1.50 Florida Board of Respiratory Therapy
Your participation information will be shared with specialty boards through the ACCME's PARS reporting system. Successful completion of a course examination is required. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
